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Abstract 
BACKGROUND: Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease that causes 
severe demyelination, especially in the optic nerve and spinal cord with typical clinical manifestations of acute 
optic neuritis and transverse myelitis. The symptoms can occur simultaneously or separated by a variable period. 
NMOSD is associated with serum aquaporin antibodies 4 immunoglobulin G (AQP4-IgG).  
CASE PRESENTATION: We report a case of a 22-year-old male with complaints of weakness of all four limbs, 
impaired vision, urinary incontinence, and dyspnea. The Expanded Disability Status Scale (EDSS) was nine. 
Spinal magnetic resonance imaging (MRI) showed longitudinal extensive transversal myelitis. The brain MRI 
showed a normal impression, whereas the brain magnetic resonance spectroscopy (MRS) examination showed a 
description of the mild demyelination process. The serum antibody AQP4 (AQP4-IgG) results were seronegative, 
the cerebrospinal fluid examination was normal, and the oligoclonal band was negative. The ophthalmoscopic 
examination found bilateral papillary atrophy but optical coherence tomography (OCT) was still normal. 
Somatosensory evoked potential and visual evoked potential examinations were abnormal. The patient was 
diagnosed with NMOSD and was given combination immunosuppressant therapy, corticosteroids, and therapeutic 
plasma exchange. The patient experienced significant improvement with EDSS decreased to six. 
CONCLUSION: In the case of relapsing NMOSD patient, combination therapy of immunosuppressant’s, 
corticosteroids, and TPE was used. There were significant improvements from EDSS nine to six. 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Neuromyelitis optica spectrum disorder 
(NMOSD), formerly known as neuromyelitis optica 
(NMO) or Devic's syndrome or Devic's disease, was 
initially considered as part of multiple sclerosis (MS) 
because the symptoms were considered overlapping. 
But now, it is known that the pathophysiology of these 
two diseases is different [1].
  
NMOSD is a central nervous system 
inflammatory syndrome that is different from MS, 
which is associated with serum aquaporin-4 
immunoglobulin G (AQP4-IgG) antibodies [1], [2], [3].
 
NMOSD is an autoimmune disease that 
causes severe demyelination, especially in the optic 
nerve with typical clinical manifestations in the form of 
acute optic neuritis and transverse myelitis which can 
occur simultaneously or separated by a variable 
period [1], [2], [3], [4], [5], [6].  
It is more common in the form of polyphasic 
(90%) such as optic neuritis or myelitis, or both 
occurring together. The monophasic form has only 
occurred in 10% of cases [1], [2]. 
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Case report 
 
We report a case of a 22-year-old male with 
complaints of weakness in all four limbs, impaired 
vision, urinary incontinence, and dyspnea. Previously 
the patient had experienced six similar attacks and the 
longer, the worse the symptoms got. A history of low 
back pain, muscle spasms, and numbness were 
found. Neurological examination found a weakness in 
all four limbs accompanied by increased physiological 
reflexes and the presence of pathological reflexes. 
Visual acuity examination on the right and left eyes 
showed a visual of 1/300 and 1/∞, respectively. 
Funduscopy examination revealed a picture of 
bilateral atrophic papillae (Figure 1). The optical 
coherence tomography (OCT) examination was 
normal. The presence of exteroceptive and 
proprioceptive disorders was accompanied by urinary 
incontinence. The score for the Expanded Disability 
Status Scale (EDSS) was nine. 
 
Figure 1: The ophthalmoscopic examination results of a 22-year-old 
male NMOSD patient with bilateral papillary atrophy 
 
Blood tests results and analysis of brain fluid 
were within normal limits. Serology for the anti-herpes 
simplex virus, PCR analysis on herpes simplex virus 
and cytomegalovirus were negative results. Serum 
aquaporin 4 examination was negative. Autoimmune 
antinuclear antibodies (ANA) and anti-DSA analysis 
were normal. Electrophysiological examination of 
somatosensory evoked potential (SEP) found lesions 
between C2-7 and Th2-7 and visual evoked potential 
(VEP) found partial blocks of bilateral visual pathways. 
The spinal MRI examination showed a picture of 
myelitis involving C3-6 and Th2-6 (Figure 2). Brain 
magnetic resonance spectroscopy (MRS) showed a 
description of mild demyelination process. Brain 
magnetic resonance imaging (MRI) showed a normal 
impression. 
Differential diagnosis at that time was 
NMOSD, MS, acute disseminated encephalomyelitis 
(ADEM), acute idiopathic myelitis transversalis (iATM) 
and systemic lupus erythematosus (SLE). Based on 
the results of clinical symptoms and other 
investigations, the patient was diagnosed with 
NMOSD. 
Treatment to prevent relapse in this patient 
was azathioprine at a dose of 50 mg given twice a 
day. Nevertheless, the patient remained to experience 
recurrences. During an acute exacerbation, he was 
treated with intravenous methylprednisolone but no 
improvement was noted and his neurological 
symptoms worsened. 
 
Figure 2: Spinal MRI result of NMOSD patient of a 22-year-old male 
with longitudinal extensive transversal myelitis involving C3-6 and 
Th2-6 
The patient was then treated with combination 
therapy of intravenous dexamethasone 5 mg and 7 
cycles of therapeutic plasma exchange (TPE) along 
with physiotherapy. He experienced significant 
improvement in his neurological symptoms with EDSS 
decreased to six. 
 
 
Discussion 
 
NMOSD is an autoimmune disease that 
causes severe demyelination, especially in the optic 
nerve and spinal cord with typical clinical 
manifestations of acute optic neuritis and transverse 
myelitis. It has been associated with serum AQP4-IgG 
[1], [2], [3], [4], [5], [6].
 
Eugene Devic (1858-1930) who first 
introduced the French term acute neuromyelitis optic 
"neuro-myélite optiquë aiugë" to show a new 
syndrome characterised by myelitis and acute optic 
neuritis. Lennon and Wingerchuck (2004) detected the 
presence of IgG-NMO or IgG-AQP4, the specific 
antibodies that distinguish NMOSD from MS [1], [7].
 
NMOSD is a rare syndrome with less than 1% 
demyelinating disease and the incidence varies in 
various countries. In general, the incidence of 
NMOSD ranges from 0.05-4.4 per 100,000 [1], [6].
 
It 
generally occurs in Asian, African and Hispanic 
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descendants [6].
 
It is more dominant to attack female 
than the man with a ratio of 3-9: 1, and in adults age 
between 30.5 and 55.2 years, but can also occur 
children and elderly [1], [6], [8].
 
NMOSD cases have 
been reported in a 3-year-old and a 90-years-old [7].
 
To date, the pathogenesis of NMOSD is still 
not fully understood [7], [9].
 
Antibodies to AQP4 play a 
key role in the pathogenesis of NMOSD. AQP4 is a 
water channel that is mostly expressed on podocytes 
of astrocytic cell membrane forming part of the blood-
brain barrier [1], [7], [9]. 
The clinical features of NMOSD are severe 
recurrent attacks of myelitis and bilateral and 
unilateral optical neuritis that can occur 
simultaneously. It is more common to be found in the 
form of polyphasic (90%) than monophasic (10%) [1], 
[2].
 
In this patient, we found a weakness in all four 
limbs, accompanied by visual impairment, urinary 
incontinence, and dyspnea. Previously, he had 
experienced 6 attacks which at each time was 
increasingly worsened. Other clinical symptoms 
include brain stem symptom, posterior reversible 
encephalopathy syndrome (PRES), coma, 
hypothalamic dysfunction, depression, cognitive 
disorders, psychiatric symptoms, and abnormal 
endocrinopathy [1], [2], [10], [11], [12]. In this patient, 
no other clinical symptom was found. 
Immunological and autoimmune examinations 
in NMOSD are generally norma[8].
 
In this patient, the 
immunological examination against the anti-herpes 
simplex virus, PCR analysis on herpes simplex virus 
and cytomegalovirus were negative. An examination 
of autoimmune antinuclear antibodies (ANA) and anti-
DSA was normal.
 
Serum AQP4-Ig is detected in 60-90% of 
patients who met NMOSD clinical and radiological 
criteria [5].
 
In seronegative AQP4-IgG patients who 
met the clinical and radiological criteria of NMOSD, 
serum myelin oligodendrocyte glycoprotein (MOG) 
antibodies can be detected [2].
 
In this patient, AQP4-
IgG examination was negative, but serum MOG 
antibody examination was not tested. 
Cerebrospinal fluid examination in positive 
NMOSD patients with AQP4-Ab can be found 
moderate with normal pleocytosis in about 40% of 
cases during acute recurrence. Oligoclonal bands 
(OCB) are usually not found, the intrathecal 
polyspecific antiviral immune response against-
Measles, Rubella and Varicella-Zoster viruses (MRZ 
reaction) are negative, and increased glial fibrillary 
acidic protein and neurofilament heavy chain (nfH) are 
commonly found [8]. In this patient, the cerebrospinal 
fluid examination gave a normal impression and OCB 
was negative. 
The results of the ophthalmoscopic 
examination in NMOSD patients varied from optic 
neuritis, atrophic papillae, to normal features [10].
 
In 
this patient, the ophthalmic examination showed 
bilateral atrophy. A thinning nerve layer may also be 
seen in the OCT examination, but the changes take a 
long time after the development of optic neuritis[3]. In 
this patient, the OCT examination showed normal 
findings. 
The electrophysiological examination on SEP 
and VEP often show changes in patients with 
NMOSD, with prolonged latency at around 40% of 
cases and decreased amplitude or potential loss in 
about 25% of patients [8].
 
In this patient, the SEP 
examination showed lesions between C2-7 and 
suspicious lesions between Th2-7. While VEP showed 
a partial block of bilateral visual pathways. 
The MRI examination on the spinal cord in 
NMOSD have typical features of longitudinal 
extensive transversal myelitis (LETM), a lesion that 
extends over 3 or more segments of the adjacent 
spinal cord [1], [5], [13], [14].
 
MRI of the optic nerve 
can be seen as hyperintensity in optic neuritis and 
tends to have more posterior involvement of the optic 
nerve. Brain MRI features can vary, such as normal or 
periependimal lesions surrounding the ventricular 
system, dorsal brain stem lesions bordering the fourth 
ventricle, periependymal lesions that surround the 
lateral ventricles, white matter hemispheres, lesions 
involving the corticospinal tract, non-specific lesions 
and enhancing lesions [14], [15].
 
In this patient, an 
MRI examination of the spinal cord showed with the 
features of myelitis involving C3-6 and Th2-6 while a 
brain MRI examination was normal.  
In general, the MRS examination for normal 
N-acetyl-aspartate (NAA), choline and Myo-inositol 
parameters are appropriate for normal axonal loss, 
inflammation, and gliosis [14], [15], [16], [17], [18].
 
In 
this patient, MRS examination found an increase in 
choline levels and the ratio of mild choline/creatine 
with the impression of a mild demyelination process. 
The differential diagnosis of NMOSD is 
multiple sclerosis, acute disseminated 
encephalomyelitis, idiopathic acute transversal 
myelitis, and systemic lupus erythematosus [1], [5], 
[15], [16], [17], [19]. 
Therapy in NMOSD consists of acute 
exacerbation phase therapy to reduce the risk of 
relapse and long-term care [10], [20].
 
Treatment 
options for prevention of relapse include oral 
corticosteroids, immunosuppressant therapy, TPE, 
immunomodulatory therapy, and other new therapies. 
Azathioprine is the main treatment option for 
preventing relapse at a dose of 75-100 mg/day and is 
more effective when combined with oral prednisolone 
(1 mg/kg/day). Evaluation on hematology and long-
term side effects including gastrointestinal complaints, 
leukopenia, infections, allergies, hematological 
general disorders, and congenital disorders are 
required [10].
 
Corticosteroids are the main choice in the 
acute phase. Intravenous methylprednisolone is 
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administered with a dose of 1-1.5 grams in 3-5 days 
[1], [2], [6], [7], [8].
 
Intravenous dexamethasone at a 
dose of 5 mg can be also a choice of corticosteroids 
[21].
 
Therapeutic plasma exchange (TPE) can be 
considered if the patient's condition does not improve 
or neurological symptoms worsen. Therapeutic 
plasma exchange dosage is carried out by giving 5-7 
cycles in a period of 2 weeks with a dose of 1-1.5 
plasma per time TPE [1], [6], [8], [9], [10], [20]. 
This patient has been treated with a dose of 
50 mg azathioprine twice a day to prevent relapse, but 
the patient still had a recurrence. In acute 
exacerbations, initially, he was given intravenous 
methylprednisolone but there was no improvement in 
neurological disorders. Next, he was treated with the 
combination therapy of intravenous dexamethasone 
and 7 cycles of TPE. Azathioprine was also continued 
to be given with physiotherapy. He experienced 
significant neurological symptoms improvement from 
EDSS nine to six. 
Long-term care is also needed such as 
medical rehabilitation, management of anxiety and 
depression, treatment of gastrointestinal problems 
and bladder, and pain management [20].
 
The probability of recurrence of disease 
activity is greater than 90% [21].
 
Attacks on NMOSD 
can be very severe, NMOSD can be life-threatening if 
the lesion extends to the cervical spinal cord and brain 
stem because it has the potential to cause respiratory 
failure [1], [7]. 
In conclusion, in the case of relapsing 
NMOSD patient, combination therapy of 
immunosuppressants, corticosteroids, and TPE was 
used. There were significant improvements from 
EDSS nine to six. 
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